japanes
enceph
je
primari
caus
viral
enceph
asia
case
report
annual
mainli
children
diagana
et
al
acut
enceph
develop
case
per
infect
lead
death
case
produc
seriou
neurolog
lesion
diagana
et
al
jackson
et
al
infect
japanes
enceph
viru
jev
often
asymptomat
one
case
produc
clinic
featur
solomon
first
sign
infect
appear
incub
period
day
diagana
et
al
diseas
usual
begin
high
fever
chill
muscl
pain
meningitistyp
headach
accompani
vomit
initi
clinic
featur
children
usual
involv
gastrointestin
symptom
nausea
vomit
abdomin
pain
nonspecif
symptom
continu
day
period
patient
condit
deterior
rapidli
eightyf
percent
subject
suffer
convuls
kumar
et
al
mening
syndrom
predomin
caus
pain
neck
stiff
addit
motor
paralys
includ
hemiplegia
tetraplegia
may
also
occur
patient
tremor
rigid
abnorm
movement
sign
extrapyramid
involv
present
kumar
et
al
recoveri
usual
leav
seriou
behavior
neurolog
sequela
persist
alter
sensorium
extrapyramid
syndrom
epilept
seizur
sever
mental
retard
children
diagana
et
al
je
mosquitoborn
arbovir
infect
caus
flaviviru
transmit
anthropophil
rice
fieldbreed
mosquito
culex
speci
mainli
culex
tritaeniorhynchu
group
vaccin
reduc
incid
je
countri
specif
antivir
therapi
current
avail
sampath
padmanabhan
point
follow
molecular
target
flaviviru
drug
discoveri
envelop
glycoprotein
proteas
helicas
methyltransferas
rnadepend
rna
polymeras
fig
protein
nonstructur
protein
jev
multifunct
protein
combin
proteas
helicas
nucleosid
ntpase
activ
sampath
padmanabhan
particular
helicasentpas
seem
promis
antivir
drug
target
enzymat
activ
essenti
viral
genom
replic
transcript
translat
yamashita
et
al
recent
crystal
structur
catalyt
domain
jev
helicasentpas
solv
use
roentgenograph
method
resolut
yamashita
et
al
jev
helicas
compos
three
domain
display
asymmetr
distribut
charg
surfac
contain
tunnel
larg
enough
accommod
singlestrand
rna
motif
walker
motif
ii
walker
b
motif
vi
contribut
ntpbind
pocket
mutat
analysi
yamashita
et
al
possibl
conclud
residu
walker
motif
addit
polar
residu
within
ntpbind
pocket
also
outsid
pocket
motif
iv
signific
ntpase
helicas
activ
viru
replic
particular
crucial
could
exchang
amino
acid
residu
without
sacrif
activ
avail
jev
helicasentpas
crystal
structur
well
mutat
analysi
residu
constitut
ntpbind
pocket
enabl
structurebas
virtual
screen
novel
inhibitor
jev
helicasentpas
virtual
screen
applic
protein
experiment
determin
structur
target
becom
establish
method
lead
discoveri
enhanc
effici
lead
optim
jain
offer
possibl
go
beyond
pool
exist
activ
compound
thu
find
novel
chemotyp
cavasotto
orri
moreov
make
possibl
evalu
potenc
million
compound
rel
short
period
time
aim
work
identifi
novel
potent
medicin
substanc
treatment
je
upon
applic
structurebas
virtual
screen
freeli
avail
zinc
databas
leadlik
compound
irwin
shoichet
verif
screen
result
dock
procedur
final
refin
result
use
consensu
score
techniqu
feher
energi
geometri
atp
compound
first
optim
ab
initio
method
approxim
applic
basi
set
obtain
structur
next
subject
conform
analysi
ga
conform
search
simul
water
solvent
final
lowestenergi
conform
optim
first
step
ga
conform
search
select
conform
analysi
produc
good
result
rel
short
time
calcul
perform
graphic
station
hp
xw
intel
coreduo
ghz
gb
ram
window
xp
profession
calcul
carri
graphic
station
ghz
gb
ram
fedora
core
dock
perform
flexibl
dock
method
surflex
jain
incorpor
surflex
fulli
automat
flexibl
molecular
dock
algorithm
combin
score
function
hammerhead
dock
system
search
engin
reli
surfacebas
molecular
similar
method
use
rapid
gener
suitabl
put
pose
molecular
fragment
jain
jev
helicasentpas
crystal
structur
pdb
file
obtain
yamashita
use
dock
procedur
case
atp
inhibitor
side
chain
conform
residu
constitut
bind
pocket
obtain
complex
optim
yasara
structur
upon
applic
forc
field
krieger
vriend
allow
optim
conform
residu
constitut
bind
pocket
made
possibl
obtain
final
enzym
structur
use
virtual
screen
dock
identifi
hit
refin
procedur
molecular
dynam
automat
obtain
result
librari
dock
treat
rel
measur
potenc
use
consensu
score
yasara
structur
calcul
perform
graphic
station
hp
xw
intel
coreduo
ghz
gb
ram
window
xp
profession
pymol
delano
vega
pedretti
et
al
chimera
pettersen
et
al
spdbv
guex
peitsch
yasara
structur
krieger
vriend
use
visual
result
graphic
produc
pymol
delano
structur
jev
helicasentpas
refin
procedur
dock
atp
follow
molecular
dynam
simul
complex
util
gener
structurebas
pharmacopohor
model
upon
applic
interact
gener
modul
discoveri
studio
crucial
residu
identifi
mutagenesi
studi
yamashita
et
al
ie
identifi
bind
site
residu
obtain
pharmacophor
model
test
screen
applic
screen
librari
modul
discoveri
studio
databas
zinc
druglik
compound
addit
contain
known
inhibitor
noncompetit
inhibitor
compound
confirm
lack
activ
toward
jev
helicasentpas
next
screen
librari
modul
discoveri
studio
appli
screen
zinc
databas
leadlik
compound
fifteen
hit
select
dock
surflex
jev
helicasentpasebind
site
final
rank
list
establish
simpl
consensu
score
procedur
sum
total
valu
obtain
dock
surflex
fit
valu
obtain
screen
librari
procedur
discoveri
studio
multipli
obtain
equal
signific
contribut
use
final
score
identifi
hit
abil
cross
barrier
lipophil
atom
contribut
method
calcul
use
preadmet
server
preadmetbmdrcorg
discoveri
studio
calcul
perform
graphic
station
hp
xw
intel
coreduo
ghz
gb
ram
window
xp
profession
first
step
research
natur
ligand
helicasentpas
atp
dock
surflex
incorpor
sybyl
atpbind
site
dock
procedur
signific
problem
bioactiv
conform
atp
bind
pose
obtain
atp
conform
linear
valu
dihedr
angl
determin
atom
ribos
neighbor
oxygen
atom
phosphoru
atom
bridg
oxygen
atom
vari
bent
conform
dihedr
angl
determin
ribos
oxygen
atom
phosphoru
atom
bridg
oxygen
phosphoru
atom
vari
bent
conform
observ
lowest
energi
conform
character
least
linear
conform
atp
energi
differ
geometr
extrem
structur
kcal
due
presenc
hydrogen
bond
stabil
atp
molecul
molecular
dynam
simul
complex
atp
conform
becam
bent
howev
lowest
energi
conform
result
bind
pose
would
accord
mutagenesi
data
yamashita
et
al
therefor
compromis
conform
accept
final
one
obtain
mode
interact
atp
enzym
consist
report
mutagenesi
analysi
yamashita
et
al
literatur
data
concern
mechan
atp
hydrolysi
helicasesntpas
frick
lam
yamashita
et
al
bind
pocket
jev
helicasentpas
form
posit
charg
residu
ie
motif
ii
vi
crucial
residu
project
pocket
recogn
moieti
atp
form
salt
bridg
stabil
bind
site
structur
motif
vi
constitut
arginin
finger
act
sensor
recogn
atp
report
critic
conform
switch
upon
atp
hydrolysi
ahmadian
et
al
niedenzu
et
al
caruth
mckay
yamashita
et
al
stress
yamashita
conserv
water
molecul
necessari
atp
hydrolysi
coordin
residu
direct
molecul
atp
toward
interact
conserv
arginin
report
essenti
rna
unwind
activ
utama
et
al
b
side
chain
conform
jev
helicasentpas
bind
pocket
residu
addit
refin
dock
procedur
known
jev
helicasentpas
inhibitor
fig
follow
molecular
dynam
simul
case
ringexpand
nucleosid
fig
ligand
structur
stabil
two
intramolecular
hydrogen
bond
one
hydroxyl
group
sugar
moieti
nitrogen
atom
imidazol
ring
one
one
keto
group
sugar
ring
oxygen
atom
keto
group
inhibitor
engag
network
hydrogen
bond
water
molecul
main
chain
nh
hydrogen
atom
also
interact
imidazol
ring
nitrogen
atom
anoth
water
molecul
imidazol
moieti
interact
next
water
molecul
amino
group
form
hydrogen
bond
side
chain
obtain
bind
pose
explain
inhibitori
activ
toward
jev
helicasentpas
interact
two
residu
jev
helicasentpas
bind
pocket
crucial
atp
bind
name
conserv
glutam
acid
residu
probabl
act
catalyt
base
accept
proton
attack
water
molecul
atp
hydrolysi
frick
lam
accompani
constitut
arginin
finger
arginin
residu
recogn
atp
dock
ringexpand
nucleosid
fig
led
similar
observ
conclus
case
inhibitor
apart
engag
format
hydrogen
bond
keto
moieti
ligand
interact
imidazol
ring
nitrogen
atom
water
molecul
thu
mention
avail
literatur
data
may
constitut
anoth
key
residu
jev
helicasentpasebind
pocket
similarli
case
amino
group
form
hydrogen
bond
side
chain
phenyl
group
fit
well
hydrophob
part
pocket
surround
apolar
side
chain
final
structur
jev
helicasentpas
refin
dock
procedur
atp
select
inhibitor
follow
molecular
dynam
simul
appli
construct
structurebas
pharmacophor
model
interact
gener
modul
discoveri
studio
pharmacophor
model
obtain
depict
fig
consist
three
hydrogen
bond
acceptor
hydrogen
bond
donor
contain
lipophil
moieti
pharmacophor
model
test
screen
databas
zinc
druglik
compound
addit
contain
known
inhibitor
noncompetit
inhibitor
fig
compound
fig
confirm
lack
activ
toward
jev
helicasentpas
screen
librari
modul
discoveri
studio
appli
result
present
tabl
obtain
structurebas
pharmacophor
model
jev
helicasentpas
verifi
posit
identifi
inhibitor
hit
model
also
prove
sensit
socal
fals
posit
none
noncompetit
inhibitor
inact
compound
recogn
potent
compound
interact
atpbind
site
way
noncompetit
mechan
action
tbbt
nogalamycin
confirm
structurebas
pharmacophor
model
obtain
jev
helicasentpas
appli
screen
zinc
databas
leadlik
compound
fifteen
hit
cf
fig
select
tabl
compound
dock
atpbind
site
jev
helicasentpas
surflex
incorpor
compar
tabl
screen
dock
result
combin
consensu
score
procedur
give
final
rank
list
hit
dock
potent
hit
fig
reveal
main
interact
ligand
involv
network
hydrogen
bond
one
nh
hydrogen
atom
thiourea
moieti
ligand
well
hydroxyl
group
phenyl
ring
place
hydrophob
caviti
form
dock
next
hit
also
reveal
engag
crucial
residu
jev
helicasentpas
potenti
inhibitor
fig
case
two
hydroxyl
group
ligand
form
hydrogen
bond
addit
side
chain
engag
hydrogen
bond
oxiran
moieti
similarli
case
ringexpand
nucleosid
keton
hydroxyl
group
interact
nh
hydrogen
atom
main
chain
case
first
hit
screen
librari
procedur
apart
alreadi
mention
form
bond
oxygen
atom
ligand
interact
one
nh
hydrogen
atom
also
seem
engag
form
hydrogen
bond
nh
hydrogen
atom
fig
fourth
hit
fig
interact
diazol
nitrogen
atom
carbonyl
group
respect
moreov
amino
group
interact
water
molecul
case
similarli
side
chain
engag
hydrogen
bond
ligand
hydroxyl
carbonyl
group
wherea
next
compound
identifi
interact
water
molecul
side
chain
main
chain
compound
also
worth
mention
possess
pentos
moieti
regard
similar
nucleosid
form
hydrogen
bond
side
chain
eight
potenti
inhibitor
identifi
interact
bind
pocket
jev
helicasentpas
similar
way
howev
character
significantli
lower
score
indic
wors
fit
bind
site
worth
emphas
among
identifi
potenti
inhibitor
one
exhibit
partial
similar
natur
ligand
atp
other
constitut
novel
chemotyp
jev
helicasentpas
inhibitor
addit
lipophil
abil
cross
barrier
identifi
hit
calcul
preadmet
server
preadmetbmdrcorg
result
present
tabl
although
compound
cross
barrier
easili
first
low
lipophil
valu
compound
good
candid
modif
direct
toward
better
admet
properti
central
nervou
systemact
drug
number
potent
inhibitor
helicas
encod
herp
simplex
viru
sever
acut
respiratori
syndrom
coronaviru
hepat
c
viru
hcv
west
nile
viru
wnv
human
papillomaviru
jev
report
recent
scientif
literatur
borowski
et
al
zhang
et
al
bretner
et
al
b
ujjinamatada
et
al
inhibitor
demonstr
decreas
viral
replic
cell
cultur
anim
model
frick
lam
jev
helicasentpas
inhibitor
belong
two
chemic
class
ringexpand
fat
nucleosid
nucleotid
zhang
et
al
benzimidazol
benzotriazol
borowski
et
al
bretner
et
al
fig
first
class
may
treat
close
analog
nucleosid
nucleotid
inhibitor
similar
natur
helicasentpas
ligand
atp
like
compet
atp
bind
site
benzimidazol
benzotriazol
well
natur
occur
compound
antibiot
nogalamycin
modul
interact
alloster
bind
site
borowski
et
al
mechan
modul
effect
remain
unclear
howev
may
specul
second
bind
site
could
occupi
nucleotid
nucleosid
even
nucleotid
base
probabl
fulfil
regulatori
function
respect
ntpase
andor
helicas
activ
enzym
borowski
et
al
research
present
provid
first
time
potenti
competit
jev
helicasentpas
inhibitor
structur
distinct
nucleosid
analog
design
medicin
substanc
constitut
prototyp
antijev
drug
rais
least
three
import
concern
first
whether
need
antijev
therapi
sever
vaccin
je
avail
secondli
possibl
laboratori
diagnosi
applic
antijev
drug
last
least
whether
design
compound
capabl
reach
central
nervou
system
discuss
later
inde
main
pillar
je
control
use
live
attenu
vaccin
human
develop
year
ago
igrashi
although
current
avail
je
vaccin
rel
safe
effect
drawback
multipl
dose
requir
furthermor
effect
deliveri
vaccin
poor
commun
remain
formid
challeng
complianc
deliveri
cost
consid
erlang
et
al
take
consider
present
system
vaccin
cover
whole
popul
danger
jev
infect
antivir
therapi
remain
use
altern
fortun
reliabl
laboratori
diagnosi
je
present
avail
diagnosi
jev
infect
made
within
epidemiolog
context
diagana
et
al
epidem
outbreak
febril
mening
syndrom
consid
je
diagnost
consider
combin
central
hyperpn
breath
associ
extrapyramid
symptom
posit
neg
predict
valu
diagana
et
al
difficult
due
transienc
viremia
isol
viru
blood
cell
obtain
venipunctur
serolog
play
import
role
confirm
diagnosi
enzymelink
immunosorb
assay
method
reveal
antibodi
igm
direct
viral
particl
case
diagana
et
al
although
activ
propos
antijev
compound
experiment
verifi
yet
reliabl
result
enhanc
fact
crystal
structur
catalyt
domain
solv
roentgenograph
method
yamashita
et
al
refin
molecular
dock
atp
known
inhibitor
follow
molecular
dynam
simul
qualiti
refin
depend
well
bind
pose
atp
well
inhibitor
predict
although
posit
atp
bound
neither
jev
helicasentpas
viral
helicasentpas
yet
visual
mechan
hydrolysi
like
resembl
seen
helicas
frick
approxim
configur
atp
bind
site
seen
compar
jev
helicas
structur
one
similar
helicas
crystal
presenc
nonhydrolyz
atp
analog
exampl
crystal
structur
escherichia
coli
recq
helicas
catalyt
core
complex
atp
analog
pdb
code
adenin
moieti
pack
side
chain
hydrogen
bond
form
atom
adenin
recq
motif
bernstein
et
al
triphosph
bound
recqdc
sever
backbon
amid
motif
ion
make
watermedi
contact
motif
motif
ii
obtain
bind
mode
atp
jev
helicasentpas
correspond
posit
recq
helicas
catalyt
core
describ
moreov
stress
conform
slightli
bent
similar
final
conform
atp
conform
bind
mode
atp
bind
pocket
jev
helicasentpas
also
consist
recent
obtain
crystal
structur
dengu
viru
helicas
complex
adp
pdb
file
luo
et
al
crystal
structur
role
conserv
lysin
two
conserv
arginin
clearli
visibl
obtain
bind
mode
atp
jev
helicasentpas
well
pose
ligand
two
crystal
structur
describ
allow
specul
role
arginin
finger
process
atp
hydrolysi
apart
recognit
triphosph
group
atp
arginin
finger
may
respons
displac
water
bind
site
role
arginin
finger
recent
demonstr
complex
qmmm
calcul
heesen
et
al
detail
analysi
jev
helicasentpas
structur
may
lead
conclus
function
catalyt
base
pka
would
need
much
higher
typic
glutam
acid
residu
protein
suggest
hcv
helicas
frick
thu
propos
neighbor
aspart
acid
residu
jev
helicasentpas
may
serv
catalyt
base
instead
dock
known
jev
helicasentpas
inhibitor
reveal
engag
crucial
bind
pocket
residu
interact
ligand
particular
role
clearli
depict
moreov
dock
allow
identif
addit
import
residu
bind
pocket
make
arginin
straightforward
candid
mutat
studi
analysi
complex
allow
specul
role
conserv
threonin
probabl
direct
ligand
properli
toward
interact
conserv
arginin
residu
similar
role
may
assign
branch
side
chain
apolar
amino
acid
especi
demonstr
case
suggest
earlier
ionotrop
glutam
receptor
kaczor
et
al
dock
indic
addit
anchor
point
wherea
dock
identifi
hit
also
indic
potenti
import
residu
interact
inhibitor
virtual
screen
procedur
made
possibl
identifi
potenti
inhibitor
jev
helicasentpas
one
name
one
contain
pentos
moieti
may
treat
far
analog
nucleosid
structur
divers
may
prove
benefici
increas
likelihood
new
inhibitor
select
toward
human
atpas
signific
problem
worth
emphas
ringexpand
nucleosid
also
high
affin
human
mitochondri
helicas
routin
use
test
select
novel
inhibitor
viral
helicasentpas
exclud
drug
candid
zhang
et
al
hand
compound
also
activ
toward
test
viral
helicasentpas
wnv
hcv
seem
promis
research
specif
antijev
compound
may
lead
develop
drug
broad
antivir
spectrum
activ
inde
structur
analysi
helicas
dengu
viru
den
yellow
fever
viru
yfv
hcv
reveal
viral
helicas
similar
structur
compos
three
function
domain
yao
et
al
wu
et
al
xu
et
al
yamashita
et
al
amino
acid
sequenc
helicas
domain
jev
exhibit
homolog
den
yfv
hcv
respect
yamashita
et
al
crystal
structur
helicas
den
xu
et
al
yfv
wu
et
al
similar
jev
slightli
differ
hcv
yao
et
al
yamashita
emphas
distanc
domain
hcv
helicas
longer
flaviviru
helicas
lead
conclus
hcv
helicas
larger
atpbind
pocket
flavivirus
fold
domain
hcv
helicas
uniqu
wherea
fold
jev
similar
flavivirus
includ
den
yfv
yamashita
et
al
superposit
jev
den
yfv
hcv
helicas
clarifi
hcv
helicas
uniqu
conform
ntpasebind
region
domain
comparison
jev
den
yfv
helicas
yamashita
et
al
particular
conform
motif
ii
hcv
helicas
differ
jev
den
yfv
helicas
distanc
motif
ii
hcv
flavivirus
respect
yamashita
et
al
also
differ
distanc
nz
motif
jev
hcv
suggest
hcv
helicas
wider
atpbind
pocket
flavivirus
yamashita
et
al
contrast
structur
motif
ii
motif
vi
well
conserv
among
flaviviru
helicas
includ
hcv
although
subtl
differ
observ
atpbind
residu
jev
den
yfv
hcv
helicas
well
conserv
suggest
flaviviru
helicas
possess
similar
mechan
atp
hydrolysi
reflect
lack
specif
compound
virtual
screen
perform
allow
noncompetit
mode
action
confirm
identifi
hit
atpbind
site
although
antivir
activ
identifi
hit
need
confirm
experiment
studi
reliabl
comput
result
obtain
enhanc
sever
factor
mention
refin
crystal
structur
catalyt
domain
jev
helicasentpas
util
construct
pharmacophor
model
moreov
residu
constitut
atpbind
site
identifi
mutat
analysi
final
applic
consensu
screen
procedur
improv
hit
rank
list
consensu
score
procedur
demonstr
improv
virtual
screen
result
significantli
feher
report
consensu
score
usual
substanti
enhanc
virtual
screen
perform
contribut
better
enrich
also
seem
improv
although
lesser
extent
predict
bound
conform
pose
particular
consensu
score
procedur
improv
predict
bind
energi
greatest
problem
virtual
screen
although
obtain
bind
energi
predict
still
inaccur
develop
requir
use
purpos
routin
lead
optim
consensu
score
procedur
present
altern
improv
silico
screen
procedur
wang
wang
distinguish
three
main
rank
method
consensu
score
virtual
screen
rankbynumb
candid
rank
accord
averag
predict
valu
given
score
function
rankbyrank
candid
rank
averag
rank
predict
involv
score
function
rankbyvot
candid
predict
top
exampl
certain
score
function
get
vote
score
function
final
score
candid
compound
number
vote
gather
score
function
may
rang
total
number
score
function
approach
appli
may
treat
modif
rankbynumb
method
use
sum
total
score
surflex
doubl
valu
fit
obtain
screen
librari
modul
discoveri
studio
although
propos
hit
character
lipophil
rang
cn
activ
drug
cross
barrier
easili
obviou
treat
prototyp
drug
requir
optim
especi
admet
properti
reach
market
studi
perform
allow
potenti
inhibitor
select
databas
compound
constitut
reason
altern
experiment
ht
procedur
moreov
novel
structur
featur
jev
helicasentpas
identifi
includ
new
import
residu
enzymebind
pocket
problem
antijev
specif
novel
compound
select
human
atpas
also
address
conclud
comput
project
perform
may
treat
guid
experiment
work
viral
helicasesntpas
antivir
drug
design
